CDNA

CareDx's stock has seen significant movement in the past six months, with a 1-year change of +332.2% as of October 9, 2026, and a 52-week range of $13.95 to $72.51. Key events include exceptional Q2 2026 financial performance and elevated full-year guidance, which led to a stock surge. The finalization of Medicare coverage for AlloSure® and AlloMap® resolved regulatory uncertainty and positively impacted the stock. A strategic corporate re-focus involved divesting the Lab Products business and acquiring Naveris, strengthening its position in specialty oncology and cell therapy. Analyst upgrades and price target revisions, such as those from BTIG Research and Zacks Research, also contributed to positive stock sentiment. However, there has been notable insider selling activity exceeding $5 million in the past three months and $13.3 million over the past 12 months without any purchases, including a director's sale of 20,000 shares. Additionally, stock vesting triggered a tax withholding for a company counsel.